Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$204.76 USD

204.76
878,984

-0.06 (-0.03%)

Updated Aug 30, 2024 04:00 PM ET

After-Market: $204.61 -0.15 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Ryan McQueeney headshot

Why Biotech Stocks Rallied on Biogen's Alzheimer's Test

Several major biotech stocks rallied on Friday after Biogen (BIIB) reported positive results from a Phase 2 study of its Ban2401 therapy, which seeks to reduce toxic amyloid proteins associated with cognitive decline and Alzheimer's disease.

    Biogen's Alzheimer Disease Candidate Succeeds in Phase II

    Biogen's (BIIB) Alzheimer's disease (AD) candidate demonstrates statistically significant slowdown in disease progression and reduction of amyloid beta accumulation in the brain in a phase II study.

      Sanofi's Blood Clotting Drug Gets Positive CHMP Opinion

      Sanofi's (SNY) Cablivi for treating acquired thrombotic thrombocytopenic purpura nears approval with CHMP recommendation.

        The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, General Motors, Valero and Ameriprise

        The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, General Motors, Valero and Ameriprise

          Mark Vickery headshot

          Top Analyst Reports for Johnson & Johnson, Biogen & General Motors

          Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Biogen (BIIB) and General Motors (GM).

            Sweta Killa headshot

            Sarepta Pharma Pushes Two Biotech ETFs to New Highs

            The encouraging early trial results for a gene therapy for Duchenne muscular dystrophy pushed Sarepta Therapeutics and few biotech ETFs to new highs.

              PTC Therapeutics' Spinal Muscular Atrophy Study Successful

              PTC Therapeutics' (PTCT) shares rally on encouraging preliminary data from a pivotal study evaluating risdiplam in babies with spinal muscular atrophy.

                Roche Announces Positive Data on Gazyva and MS Drug Ocrevus

                Roche (RHHBY) announced positive long-term data on leukemia drug Gazyva and MS drug Ocrevus.

                  Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant

                  Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant

                    Tracey Ryniec headshot

                    Drug Stocks: The Next Hot Industry or Value Traps?

                    These 5 stocks look dirt cheap but is it too good to be true?

                      Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod

                      Key areas of focus in the biotech space include regulatory approvals and licensing/acquisition deals.

                        Biogen Inks Deal With TMS To Acquire Phase II Stroke Asset

                        Biogen (BIIB) signs a definitive option agreement to buy TMS-007, a phase II candidate, for the treatment of acute ischemic stroke (AIS) from private biotech TMS Co., Ltd.

                          Roche Rituxan Label Expanded by FDA for Pemphigus Vulgaris

                          Roche (RHHBY) obtains FDA approval for the label expansion of Rituxan for the treatment of adults with pemphigus vulgaris.

                            Pfizer Boosts Venture Capital Efforts, Neuroscience in Focus

                            Pfizer (PFE) to pour $600 million in its venture capital arm. About 150 million will be earmarked for companies involved in promising early-stage neuroscience research.

                              Why is Biogen (BIIB) Up 6.7% Since Its Last Earnings Report?

                              Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                Novartis Multiple Sclerosis Drug Gets FDA Nod for Adolescents

                                The FDA approves Novartis' (NVS) multiple sclerosis drug Gilenya for the treatment of children and adolescents aged between 10 and 18.

                                  What's in the Cards for Ionis (IONS) This Earnings Season?

                                  Ionis Pharmaceuticals (IONS) earns $30 million in license payments from AstraZeneca. Spinraza witnesses strong first quarter as announced by Biogen in its earnings release.

                                    Alkermes (ALKS) Reports Wider-Than-Expected Loss in Q1

                                    Alkermes (ALKS) posts wider than expected loss in the first quarter of 2018. However, sales beat estimates.

                                      Biotech Stock Roundup: PRTA Down, AMGN Revises View, BIIB Misses on Sales

                                      The biotech sector grabbed headlines last week as a couple of biotechs reported results while few others came out with pipeline updates.

                                        Biogen (BIIB) Q1 Earnings Beat, Sales Miss, Shares Down

                                        Biogen's (BIIB) earnings beat estimates but sales miss the same marginally in Q1. The company's latest key drug Spinraza's tepid sales compares with its sequential tally.

                                          Biogen (BIIB) Q1 Earnings Beat, Sales Miss

                                          Biogen (BIIB) beat estimates for earnings but marginally misses the same for sales in Q1. The company's oral MS drug Tecfidera sales increased year over year.

                                            Roche (RHHBY) Presents Encouraging Data on MS Drug Ocrevus

                                            Roche (RHHBY) announces encouraging data on multiple sclerosis (MS) drug Ocrevus which reinforced the efficacy of drug in the long run.

                                              Novartis (NVS) Reports Encouraging Data on MS Candidate

                                              Novartis (NVS) announces encouraging results from a phase III study, EXPAND, on siponimod (BAF312) in patients with secondary progressive multiple sclerosis.

                                                What's in Store for Biogen (BIIB) This Earnings Season?

                                                On the Q1 call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise and Spinraza's performance.

                                                  Mylan Fujifilm Kyowa Team Up to Market Humira Biosimilar

                                                  Mylan (MYL) is partnering with Fujifilm Kyowa to commercialize a biosimilar to Humira (adalimumab).